Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia-Reference-Cited by-同舟云学术

Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia

Published:2017-06-17 Issue:8 Volume:96 Page:1353-1360
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Zhao Yanmin,Wang Jiasheng,Luo Yi,Shi Jimin,Zheng Weiyan,Tan Yamin,Cai Zhen,Huang He

Funder

National Natural Science Foundation of China

Natural Science Foundation of Zhejiang Province (CN)

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-017-3021-y/fulltext.html

Reference21 articles.

1. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27(35):6041–6051. doi: 10.1200/JCO.2009.25.0779

2. Jabbour EJ, Kantarjian H, Eliasson L, Cornelison AM, Marin D (2012) Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 87(7):687–691. doi: 10.1002/ajh.23180

3. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL (2014) Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32(4):306–311. doi: 10.1200/JCO.2013.52.9123

4. Jootar S (2012) CML treatment in Asia-Pacific region. Hematology 17(Suppl 1):S72–S74. doi: 10.1179/102453312X13336169155772

5. Mendizabal AM, Garcia-Gonzalez P, Levine PH (2013) Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. Cancer Epidemiol 37(3):247–254. doi: 10.1016/j.canep.2013.01.002

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT;American Journal of Hematology;2022-10-31

2. Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents/Young Adults With CML in the TKI Era;Transplantation and Cellular Therapy;2022-07

3. Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology;Medicina;2019-07-28

4. Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic stem cell transplantation for refractory hemophagocytic lymphohistiocytosis;Bone Marrow Transplantation;2019-06-04